Immunotherapy for lung cancer: ongoing clinical trials

Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer

(2013) Rupal Ramakrishnan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

(2013) Johan Vansteenkiste et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

(2013) Fernando Ulloa-Montoya et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

(2013) Silvia C. Formenti et al.   JNCI-Journal of the National Cancer Institute

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development

(2011) L. Decoster et al.   ANNALS OF ONCOLOGY

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer That Progressed After Chemotherapy

(2011) Purvish M. Parikh et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer

(2011) Raghunadharao Digumarti et al.   Journal of Thoracic Oncology

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

(2011) Elisabeth Quoix et al.   LANCET ONCOLOGY

Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

(2011) Håkan Mellstedt et al.   LUNG CANCER

Targeting the Immune System in Non–Small-Cell Lung Cancer: Bridging the Gap Between Promising Concept and Therapeutic Reality

(2010) Ronan J. Kelly et al.   Clinical Lung Cancer

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

(2010) Rodryg Ramlau et al.   Journal of Thoracic Oncology

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer

(2010) Katsuhiko Shimizu et al.   Journal of Thoracic Oncology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

(2008) B. Kavanagh et al.   BLOOD

Predominant infiltration of macrophages and CD8+T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer

(2008) Osamu Kawai et al.   CANCER

Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

(2008) Y. Diaz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer

(2008) K. I. Al-Shibli et al.   CLINICAL CANCER RESEARCH

Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer

(2008) Elia Neninger Vinageras et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

(2008) Lawrence Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Functions of natural killer cells

(2008) Eric Vivier et al.   NATURE IMMUNOLOGY

Cancer Immunology

(2008) Olivera J. Finn   NEW ENGLAND JOURNAL OF MEDICINE